176 related articles for article (PubMed ID: 26060141)
1. Use of phosphodiesterase type 5 inhibitors in assistive living and home care settings.
Iannino-Renz R; Mager D
Appl Nurs Res; 2015 Aug; 28(3):251-3. PubMed ID: 26060141
[TBL] [Abstract][Full Text] [Related]
2. [Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future].
Gamidov SI; Ovchinnikov RI; Popova AY; Izhbaev SK
Urologiia; 2017 Apr; (1):103-107. PubMed ID: 28394532
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
Bacconi L; Gressier F
Encephale; 2017 Feb; 43(1):55-61. PubMed ID: 27658991
[TBL] [Abstract][Full Text] [Related]
4. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Mostafa T
Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
[TBL] [Abstract][Full Text] [Related]
5. A Case Report: Consecutive Cranial Neuropathies Following the Use of Phosphodiesterase-5 Inhibitors.
van Landingham SW; Singman EL
Am Orthopt J; 2015; 65():109-14. PubMed ID: 26564936
[TBL] [Abstract][Full Text] [Related]
6. [Current role of sildenafil in the management of erectile dysfunction].
Akhvlediani ND; Matyukhov IP
Urologiia; 2018 May; (2):142-146. PubMed ID: 29901310
[TBL] [Abstract][Full Text] [Related]
7. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis.
Hsu JC; Tang DH; Lu CY
Int J Clin Pract; 2015 Apr; 69(4):436-43. PubMed ID: 25311239
[TBL] [Abstract][Full Text] [Related]
8. PDE-5 inhibitors: clinical points.
Doumas M; Lazaridis A; Katsiki N; Athyros V
Curr Drug Targets; 2015; 16(5):420-6. PubMed ID: 25392015
[TBL] [Abstract][Full Text] [Related]
9. [PDE-5 inhibitors: patients preferences].
Efremov EA; Kasatonova EV; Melnik YI; Nikushina AA
Urologiia; 2017 Jul; (3):120-126. PubMed ID: 28845950
[TBL] [Abstract][Full Text] [Related]
10. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.
Gong B; Ma M; Xie W; Yang X; Huang Y; Sun T; Luo Y; Huang J
Int Urol Nephrol; 2017 Oct; 49(10):1731-1740. PubMed ID: 28741090
[TBL] [Abstract][Full Text] [Related]
11. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.
Rubio-Aurioles E; Porst H; Kim ED; Montorsi F; Hackett G; Morales AM; Stuckey B; Būttner H; West TM; Huynh NN; Lenero E; Burns P; Kopernicky V
J Sex Med; 2012 May; 9(5):1418-29. PubMed ID: 22429760
[TBL] [Abstract][Full Text] [Related]
12. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
13. [Dosage forms of sildenafil in the management of erectile dysfunction].
Grigoryan VA; Gazimiev MA; Demidko YL; Baiduvaliev AM
Urologiia; 2018 Mar; (1):159-162. PubMed ID: 29634153
[TBL] [Abstract][Full Text] [Related]
14. [Phosphodesterase type 5 inhibitors clinical efficiency and role in therapy for erectile dysfunction].
Shodmonova ZR; Gafarov RR; Allazov SA; Giyasov SI
Urologiia; 2021 May; (2):135-140. PubMed ID: 33960173
[TBL] [Abstract][Full Text] [Related]
15. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Loeb S; Folkvaljon Y; Lambe M; Robinson D; Garmo H; Ingvar C; Stattin P
JAMA; 2015 Jun 23-30; 313(24):2449-55. PubMed ID: 26103029
[TBL] [Abstract][Full Text] [Related]
16. Patient diagnosed with chronic erectile dysfunction refractory to PDE 5 Inhibitor therapy reports improvement in function after hyperbaric oxygen therapy.
Cormier J; Theriot M
Undersea Hyperb Med; 2016; 43(4):463-465. PubMed ID: 28763176
[TBL] [Abstract][Full Text] [Related]
17. [Erectile dysfunction, PDE5A inhibitors and melanoma].
Schmutz JL
Ann Dermatol Venereol; 2015 Dec; 142(12):800-1. PubMed ID: 26293983
[No Abstract] [Full Text] [Related]
18. Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.
Porst H; Hell-Momeni K; Büttner H
Expert Opin Pharmacother; 2012 Jul; 13(10):1481-94. PubMed ID: 22725705
[TBL] [Abstract][Full Text] [Related]
19. Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis.
Houslay MD
Trends Cancer; 2016 Apr; 2(4):163-165. PubMed ID: 28741569
[TBL] [Abstract][Full Text] [Related]
20. The Phosphodiasterase 5-Inhibitors (PDE-5i) for Erectile Dysfunction (ED): A Therapeutic Challenge For Psychiatrists.
Koon CS; Sidi H; Kumar J; Xi OW; Das S; Hatta MH; Alfonso C
Curr Drug Targets; 2018; 19(12):1366-1377. PubMed ID: 28215172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
